Cordio Medical’s HearO app granted FDA Breakthrough Device Designation

Peregrine portfolio company Cordio Medical has received FDA Breakthrough Device Designation for HearO™, its digital health platform for remote monitoring of patients with congestive heart failure (CHF).

HearO uses artificial intelligence and speech signal processing to analyze subtle changes in a patient’s voice associated with pulmonary fluid accumulation, enabling earlier detection of worsening heart failure and potentially allowing clinical intervention before hospitalization.

Media coverage: The Times of Israel